17D yellow fever vaccines

New insights. A report of a workshop held during the World Congress on Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005

Alan Barrett, Thomas P. Monath, Veronique Barban, Matthias Niedrig, Dirk E. Teuwen

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Yellow fever (YF) is a major health problem in endemic regions of Africa and South America. It also poses a serious health risk to travellers to areas with endemic disease. Currently, there is no effective drug treatment for YF; however, 17D YF vaccines have demonstrated high rates of effectiveness and good safety profiles. This workshop was organized to review key data and issues about YF disease and currently available 17D YF vaccines. Starting with an overview of the current disease epidemiology in Africa and South America and a review of the safety data of 17D YF vaccines, data were then presented demonstrating the genetic stability of multiple production lots of a 17D YF vaccine, the immunological responses of healthy subjects post-vaccination and the long-term immunogenicity of 17D YF vaccines. Finally, the findings of the molecular characterization of 17D YF virus sub-strains recovered from rare, fatal cases of post-vaccination serious adverse events were presented. There was unanimous agreement that current 17D YF vaccines have a highly favourable benefit-risk profile when used in persons at risk of exposure to the YF virus, and that appropriate use of 17D YF vaccines will minimize the occurrence of serious adverse events post-vaccination.

Original languageEnglish
Pages (from-to)2758-2765
Number of pages8
JournalVaccine
Volume25
Issue number15
DOIs
StatePublished - Apr 12 2007

Fingerprint

Yellow Fever Vaccine
Yellow fever virus
France
tropics
medicine
Medicine
vaccines
Education
Yellow Fever
Health
Vaccination
South America
Safety
vaccination
Endemic Diseases
immune response
Healthy Volunteers
Epidemiology
risk profile
genetic stability

Keywords

  • Adverse events
  • Vaccines
  • Yellow fever

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

17D yellow fever vaccines : New insights. A report of a workshop held during the World Congress on Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005. / Barrett, Alan; Monath, Thomas P.; Barban, Veronique; Niedrig, Matthias; Teuwen, Dirk E.

In: Vaccine, Vol. 25, No. 15, 12.04.2007, p. 2758-2765.

Research output: Contribution to journalArticle

@article{387cbdb197ec417da222ff4a397ed977,
title = "17D yellow fever vaccines: New insights. A report of a workshop held during the World Congress on Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005",
abstract = "Yellow fever (YF) is a major health problem in endemic regions of Africa and South America. It also poses a serious health risk to travellers to areas with endemic disease. Currently, there is no effective drug treatment for YF; however, 17D YF vaccines have demonstrated high rates of effectiveness and good safety profiles. This workshop was organized to review key data and issues about YF disease and currently available 17D YF vaccines. Starting with an overview of the current disease epidemiology in Africa and South America and a review of the safety data of 17D YF vaccines, data were then presented demonstrating the genetic stability of multiple production lots of a 17D YF vaccine, the immunological responses of healthy subjects post-vaccination and the long-term immunogenicity of 17D YF vaccines. Finally, the findings of the molecular characterization of 17D YF virus sub-strains recovered from rare, fatal cases of post-vaccination serious adverse events were presented. There was unanimous agreement that current 17D YF vaccines have a highly favourable benefit-risk profile when used in persons at risk of exposure to the YF virus, and that appropriate use of 17D YF vaccines will minimize the occurrence of serious adverse events post-vaccination.",
keywords = "Adverse events, Vaccines, Yellow fever",
author = "Alan Barrett and Monath, {Thomas P.} and Veronique Barban and Matthias Niedrig and Teuwen, {Dirk E.}",
year = "2007",
month = "4",
day = "12",
doi = "10.1016/j.vaccine.2006.12.015",
language = "English",
volume = "25",
pages = "2758--2765",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "15",

}

TY - JOUR

T1 - 17D yellow fever vaccines

T2 - New insights. A report of a workshop held during the World Congress on Medicine and Health in the Tropics, Marseille, France, Monday 12 September 2005

AU - Barrett, Alan

AU - Monath, Thomas P.

AU - Barban, Veronique

AU - Niedrig, Matthias

AU - Teuwen, Dirk E.

PY - 2007/4/12

Y1 - 2007/4/12

N2 - Yellow fever (YF) is a major health problem in endemic regions of Africa and South America. It also poses a serious health risk to travellers to areas with endemic disease. Currently, there is no effective drug treatment for YF; however, 17D YF vaccines have demonstrated high rates of effectiveness and good safety profiles. This workshop was organized to review key data and issues about YF disease and currently available 17D YF vaccines. Starting with an overview of the current disease epidemiology in Africa and South America and a review of the safety data of 17D YF vaccines, data were then presented demonstrating the genetic stability of multiple production lots of a 17D YF vaccine, the immunological responses of healthy subjects post-vaccination and the long-term immunogenicity of 17D YF vaccines. Finally, the findings of the molecular characterization of 17D YF virus sub-strains recovered from rare, fatal cases of post-vaccination serious adverse events were presented. There was unanimous agreement that current 17D YF vaccines have a highly favourable benefit-risk profile when used in persons at risk of exposure to the YF virus, and that appropriate use of 17D YF vaccines will minimize the occurrence of serious adverse events post-vaccination.

AB - Yellow fever (YF) is a major health problem in endemic regions of Africa and South America. It also poses a serious health risk to travellers to areas with endemic disease. Currently, there is no effective drug treatment for YF; however, 17D YF vaccines have demonstrated high rates of effectiveness and good safety profiles. This workshop was organized to review key data and issues about YF disease and currently available 17D YF vaccines. Starting with an overview of the current disease epidemiology in Africa and South America and a review of the safety data of 17D YF vaccines, data were then presented demonstrating the genetic stability of multiple production lots of a 17D YF vaccine, the immunological responses of healthy subjects post-vaccination and the long-term immunogenicity of 17D YF vaccines. Finally, the findings of the molecular characterization of 17D YF virus sub-strains recovered from rare, fatal cases of post-vaccination serious adverse events were presented. There was unanimous agreement that current 17D YF vaccines have a highly favourable benefit-risk profile when used in persons at risk of exposure to the YF virus, and that appropriate use of 17D YF vaccines will minimize the occurrence of serious adverse events post-vaccination.

KW - Adverse events

KW - Vaccines

KW - Yellow fever

UR - http://www.scopus.com/inward/record.url?scp=33947124138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947124138&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.12.015

DO - 10.1016/j.vaccine.2006.12.015

M3 - Article

VL - 25

SP - 2758

EP - 2765

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 15

ER -